Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Targeting type I interferon–mediated activation restores immune function in chronic HIV infection
Anjie Zhen, … , David G. Brooks, Scott G. Kitchen
Anjie Zhen, … , David G. Brooks, Scott G. Kitchen
Published December 12, 2016
Citation Information: J Clin Invest. 2017;127(1):260-268. https://doi.org/10.1172/JCI89488.
View: Text | PDF
Research Article AIDS/HIV Immunology Article has an altmetric score of 185

Targeting type I interferon–mediated activation restores immune function in chronic HIV infection

  • Text
  • PDF
Abstract

Chronic immune activation, immunosuppression, and T cell exhaustion are hallmarks of HIV infection, yet the mechanisms driving these processes are unclear. Chronic activation can be a driving force in immune exhaustion, and type I interferons (IFN-I) are emerging as critical components underlying ongoing activation in HIV infection. Here, we have tested the effect of blocking IFN-I signaling on T cell responses and virus replication in a murine model of chronic HIV infection. Using HIV-infected humanized mice, we demonstrated that in vivo blockade of IFN-I signaling during chronic HIV infection diminished HIV-driven immune activation, decreased T cell exhaustion marker expression, restored HIV-specific CD8 T cell function, and led to decreased viral replication. Antiretroviral therapy (ART) in combination with IFN-I blockade accelerated viral suppression, further decreased viral loads, and reduced the persistently infected HIV reservoir compared with ART treatment alone. Our data suggest that blocking IFN-I signaling in conjunction with ART treatment can restore immune function and may reduce viral reservoirs during chronic HIV infection, providing validation for IFN-I blockade as a potential therapy for HIV infection.

Authors

Anjie Zhen, Valerie Rezek, Cindy Youn, Brianna Lam, Nelson Chang, Jonathan Rick, Mayra Carrillo, Heather Martin, Saro Kasparian, Philip Syed, Nicholas Rice, David G. Brooks, Scott G. Kitchen

×

Figure 2

IFN-I signaling is chronically elevated during HIV-1 infection.

Options: View larger image (or click on image) Download as PowerPoint
IFN-I signaling is chronically elevated during HIV-1 infection.
(A) Chan...
(A) Change of HIV cell–associated RNA levels in peripheral blood mononuclear cells (PBMCs) from BLT mice after HIV infection as compared with expression of the human housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT). Detection limit is shown by dashed orange line (n = 12–20). (B) CD4% among T cells in PBMCs from BLT mice after HIV infection (n = 12–20 per group). CD4%, percent of CD4+ cells among T cells in PBMCs. (C) CD4/CD8 ratio of T cells in PBMCs from BLT mice after HIV infection (n = 12–20 per group). (D) Expression levels of the MX1 gene in PBMCs throughout chronic HIV-1 infection in comparison with uninfected animals (n = 11–20 per group). Red dashed line defines the relative levels of MX1 gene expression in uninfected mice, which is equal to 1. (E) Expression level of MX1 and OAS1 in PBMCs and splenocytes from uninfected and infected mice as measured by reverse transcriptase PCR (RT-PCR) (n = 4–16 per group). *P < 0.05, Mann-Whitney U test. Data represent mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 23 news outlets
Blogged by 1
Posted by 6 X users
Referenced in 5 patents
On 4 Facebook pages
137 readers on Mendeley
See more details